November 18th, 2024: Ratio Enters License and Collaboration …

5 days ago · Ratio to to receive upfront, and potential milestones and tiered royalty payments BOSTON, November 18, 2024 /PRNewswire/ -- Ratio Therapeutics Inc. (Ratio), a …

CouponFollow Extension

$745
OFF

Ratio Therapeutics Lands $745M Cancer Drug Development Deal …

6 days from now

4 days ago · Ratio Therapeutics has entered into an exclusive worldwide license and collaboration agreement with Novartis Pharma AG to develop a Somatostatin Receptor 2 (SSTR2) …

stocktitan.net

$63
OFF

Novartis Strengthens Radiopharma Leadership With Ratio …

6 days from now

Venture financing for innovative radiopharmaceutical drugs witnessed an increase from $63m in 2017 to over $400m in 2023 total deal value in the US, according to GlobalData’s Pharma …

msn.com

$745
OFF

Novartis, Ratio To Collaborate On SSTR2 Radiotherapeutic For …

6 days from now

Under the deal, Ratio will receive up to $745M in upfront and potential milestone payments, plus tiered royalties on future sales. Ratio will collaborate with Novartis on preclinical activities to ...

msn.com

$750
OFF

Ratio Nets Potential $750M Radioligand Cancer Deal With Novartis

6 days from now

4 days ago · Ratio Therapeutics has inked an exclusive worldwide agreement potentially worth $745M with Novartis Pharma AG. The collaboration leverages Ratio’s radioligand therapy …

insideprecisionmedicine.com

$745
OFF

Novartis Drops Up To $745M To Move Deeper Into Competitive

6 days from now

4 days ago · Novartis has struck a deal worth up to $745 million with Ratio Therapeutics for a radiopharmaceutical that could help defend its franchise from would-be challengers including …

biospace.com

$745
OFF

Novartis Expands Radiopharmaceutical Portfolio With $745M Deal …

6 days from now

5 days ago · Novartis has struck a licensing agreement with Boston-based biotech Ratio Therapeutics, securing global rights to a promising cancer candidate targeting somatostatin …

biopharmatrend.com

$745
OFF

Novartis Continues Push Into Radiopharma With $745M Ratio Deal

6 days from now

5 days ago · With two approved radioligand therapies on its commercial roster and a recent plan to boost its manufacturing for radiotherapeutics, Novartis AG tapped Ratio Therapeutics Inc. in …

bioworld.com

$745
OFF

Novartis Strikes Radiopharma Deal With Ratio Worth Up To $745M

6 days from now

4 days ago · Novartis and Ratio Therapeutics announced a collaboration deal worth up to $745 million, focusing on SSTR2 radiotherapeutic cancer treatment. Ratio will receive an …

endpts.com

$50
OFF

Ratio Therapeutics Secures $50M Series B To Develop Cancer …

6 days from now

Jan 18, 2024 · Boston-based pharmaceutical company Ratio Therapeutics has announced the completion of a $50 million Series B financing round to advance its targeted radiotherapies for …

builtinboston.com

FAQs about November 18th, 2024: Ratio Enters License and Collaboration … Coupon?

Does Novartis have a partnership with ratio Therapeutics?

Novartis (NYSE:NVS) has entered into an exclusive worldwide license and collaboration agreement with Ratio Therapeutics for the development of a SSTR2 radiotherapeutic candidate for the treatment of cancer. Under the deal, Ratio will receive up to $745M in upfront and potential milestone payments, plus tiered royalties on future sales. ...

What does ratio Therapeutics do?

Developing best-in-class radiopharmaceuticals for cancer patients A discovery through early clinical phase pharmaceutical company, Ratio Therapeutics employs a suite of innovative technologies to develop best-in-class targeted radiotherapeutics for the treatment of cancers. ...

Is N ovartis partnering with ratio Therapeutics?

N ovartis (NYSE: NVS) has entered into an exclusive worldwide license and collaboration agreement with Ratio Therapeutics for the development of a SSTR2 radiotherapeutic candidate for the treatment of cancer. Under the deal, Ratio will receive up to $745M in upfront and potential milestone payments, plus tiered royalties on future sales. ...

What is Novartis doing with radioligand therapy?

In the announcement accompanying the deal, Novartis’ president of biomedical research Fiona Marshall said: “Radioligand therapies hold transformative potential for certain forms of cancer, and Novartis is committed to maximising their impact by continually improving the benefit for patients.” ...